A pT1c breast cancer is a tumor measuring between 10 and 20 millimeters (roughly 1 to 2 centimeters) at its widest point. When no cancer has spread to the lymph nodes or other parts of the body, pT1c is classified as Stage IA. But the final stage assignment can shift depending on the tumor’s biology, so pT1c alone doesn’t tell the whole story.
What pT1c Means on a Pathology Report
The lowercase “p” stands for pathological, meaning the tumor was measured after surgical removal and examined under a microscope. This is different from clinical staging (sometimes written as cT1c), which is an estimate based on imaging like mammography or ultrasound before surgery. Pathological staging is more precise because a pathologist can measure the actual invasive portion of the tumor down to the millimeter.
T1c is one of four subcategories within the T1 classification. T1 covers all invasive tumors 20 mm or smaller, broken down like this:
- T1mi: 1 mm or smaller
- T1a: greater than 1 mm up to 5 mm
- T1b: greater than 5 mm up to 10 mm
- T1c: greater than 10 mm up to 20 mm
Only the invasive component counts toward this measurement. If the pathology report also mentions in situ disease (cancer cells that haven’t broken through the milk duct wall), that portion is not included in the size used to determine the T category.
How pT1c Translates to an Overall Stage
Breast cancer staging combines three pieces of information: tumor size (T), lymph node involvement (N), and whether cancer has spread to distant organs (M). For a pT1c tumor with no lymph node involvement and no distant spread (written as pT1c N0 M0), the anatomical stage is IA. This falls within what most people think of as “early-stage” breast cancer.
If lymph nodes do contain cancer cells, the stage climbs. A pT1c tumor with spread to nearby lymph nodes can land anywhere from Stage IIA to Stage IIIA, depending on how many nodes are involved and to what degree.
Prognostic Stage vs. Anatomical Stage
Since 2018, the staging system used in the United States (the AJCC 8th edition) has included a second layer called the prognostic stage. This factors in biological characteristics of the tumor that strongly influence how it behaves: whether the cancer is fueled by estrogen or progesterone (hormone receptor status), whether it overproduces a growth protein called HER2, and the tumor’s grade (how abnormal the cells look under a microscope).
These biological factors can move the stage up or down from the anatomical stage. A pT1c tumor that is hormone receptor-positive, HER2-negative, and low grade may be assigned a more favorable prognostic stage than its anatomy alone would suggest. On the other hand, a triple-negative tumor (negative for estrogen receptors, progesterone receptors, and HER2) with a high grade can be upstaged because it tends to behave more aggressively. In studies of the updated staging system, triple-negative tumors with lymph node involvement showed notably worse outcomes, with five-year survival around 71% compared to higher rates for other biological subtypes at the same anatomical stage.
This means two people with the exact same pT1c tumor size can end up with different official stages. Your pathology report will typically list both the anatomical stage and the prognostic stage, and your oncologist will use the prognostic stage to guide treatment decisions.
Survival and Outlook for pT1c Tumors
Lymph node status is the single biggest factor in prognosis for a pT1c tumor. When no lymph nodes are involved (pT1c N0), survival rates are high. Research has found five-year survival for pT1c N0 breast cancer at roughly 96%, compared to around 62% when lymph nodes were positive. That gap underscores why the same tumor size can have very different outcomes depending on whether cancer has reached the lymph nodes.
Tumor biology also plays a significant role. Hormone receptor-positive cancers generally respond well to hormone-blocking therapies taken over several years after surgery, which improves long-term outcomes. HER2-positive cancers, once considered more aggressive, now have targeted therapies that have substantially improved survival. Triple-negative cancers lack these treatment targets and tend to carry a less favorable prognosis at any tumor size, though chemotherapy remains effective for many patients.
What Your Pathology Report Should Tell You
If your report says pT1c, the key numbers and details to look for alongside it include the exact tumor size in millimeters, the lymph node status (N0 means none involved), hormone receptor results (ER and PR, reported as positive or negative), HER2 status, and tumor grade (1, 2, or 3). Together, these determine both your anatomical stage and your prognostic stage, and they shape the treatment plan your care team will recommend.
The grade deserves particular attention. Grade 1 means the cancer cells still look somewhat like normal breast cells and tend to grow slowly. Grade 3 means they look very abnormal and are more likely to grow quickly. Grade 2 falls in between. A pT1c, grade 1, hormone receptor-positive, node-negative tumor is among the most treatable breast cancers, while a pT1c, grade 3, triple-negative tumor with positive nodes carries a more guarded outlook despite being the same physical size.